Human papillomavirus (HPV) related disease remains a major cause of morbidity and mortality worldwide. Prophylactic
vaccines have been recognized as the most effective intervention to control for HPV-related diseases. This article reviews the major phaseii/iii trials of the bivalent (HPVs16/18), quadrivalent (HPVs6/11/16/18), and the recently approved 9-valent
vaccine (HPVs6/11/16/18/31/33/45/52/58). Large trials have been conducted showing the safety, immunogenicity and high efficacy of the bivalent and
quadrivalent vaccines in the prevention of pre-invasive lesions and
infection, especially when administered at young ages before exposure to HPV. Trials of the 9-valent
vaccine have also demonstrated the safety, immunogenicity and efficacy of the
vaccine in the prevention of
infection and disease associated with the
vaccine types, and its potential to substantially increase the overall prevention of HPV-related diseases. Post-licensure country reports have shown the recent and early impact of these
vaccines at population level after the implementation of established HPV vaccination programs, including decreases in the prevalence of
vaccine HPV types, the incidence of
genital warts, and the incidence of high-grade cervical abnormalities. If widely implemented, current
HPV vaccines may drastically reduce the incidence of
cervical cancer and other HPV-related
cancers and diseases.